Propofol + analgesic drug — Competitive Intelligence Brief

Propofol + analgesic drug (Propofol + analgesic drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sedative-hypnotic. Area: Anesthesiology.

phase 3 Sedative-hypnotic GABA receptor Anesthesiology Small molecule

Target snapshot

Propofol + analgesic drug (Propofol + analgesic drug) — University Hospital, Brest. Propofol is a sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia, while the analgesic component provides pain relief.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propofol + analgesic drug TARGET	Propofol + analgesic drug	University Hospital, Brest	phase 3	Sedative-hypnotic	GABA receptor
Passiflora incarnata	Passiflora incarnata	Nutricion Medica S.L.	marketed	Herbal anxiolytic/sedative	GABA receptors, serotonin receptors (non-selective)
chamomile tea	chamomile tea	National Center for Complementary and Integrative Health (NCCIH)	marketed	Herbal anxiolytic/sedative	GABA receptors, benzodiazepine receptors
nortriptyline + topiramate	nortriptyline + topiramate	University of California, Irvine	marketed	Tricyclic antidepressant + anticonvulsant combination	Norepinephrine transporter, serotonin transporter, voltage-gated sodium channels, GABA receptors
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels
Sevoflurane+Nitrous oxide	Sevoflurane+Nitrous oxide	Huazhong University of Science and Technology	marketed	General anesthetic (volatile anesthetic + inhalational anesthetic)	GABA receptors, NMDA receptors
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sedative-hypnotic class)

1. Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
2. Life Extension Foundation Inc. · 1 drug in this class
3. Seoul National University Hospital · 1 drug in this class
4. University Hospital, Brest · 1 drug in this class